ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.969,86
-1,44%
S&P 500
5.867,08
-0,09%
Dow Jones
42.342,24
0,04%
Euro vs US Dollar
1,03643
0,00%
Bitcoin
97.219,13
-0,25%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Mesoblast Limited (MESO) Börsenkurse

Mesoblast Limited

Mesoblast Limited (MESO)

NASDAQ
16,76
4,51
(36,82%)
Beim Schlusskurs: 20 Dezember 10:00PM
Verzögert um 15 Minuten
15,85
-0,91
( -5,43% )
Nach Börsenschluss: 1:27AM
Verzögert um 15 Minuten

Professionelle Tools für Privatanleger.

Premium

Wichtige Statistiken und Details

Current Price
15,85
Gebot
15,75
Fragen
16,00
Volumen
3.986.376
14,35 Tagesbereich 19,1489
0,00 52-Wochen-Bereich 0,00
Marktkapitalisierung
1,81B
Handelsende
12,25
Handelsbeginn
18,65
Letzte Trade
1
@
15.99
Letzter Handelszeitpunkt
01:33:08
Finanzvolumen
US$ 65.999.968
VWAP
16,5564
Durchschnittliches Volumen (3 Mio.)
-
Ausgegebene Aktien
114.178.411
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-3,25
Gewinn pro Aktie (EPS)
-0,77
Erlöse
9,25M
Nettogewinn
-87,96M

Über Mesoblast Limited

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-... Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others. Mehr anzeigen

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Website
www.mesoblast.com
Hauptsitz
Melbourne, Victoria, Aus
Gegründet
-
Mesoblast Limited is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker MESO. The last closing price for Mesoblast was US$12,25. Over the last year, Mesoblast shares have traded in a share price range of US$ 0,00 to US$ 0,00.

Mesoblast currently has 114.178.411 shares in issue. The market capitalisation of Mesoblast is US$1,40 billion. Mesoblast has a price to earnings ratio (PE ratio) of -3.25.

Option-Flow Mesoblast (MESO)

Vollständigen Option-Flow anzeigen

Gesamtfluss

Bullisch

Nettoprämie

1M

Calls / Puts

314,29%

Käuf. / Verkä.

91,67%

OTM / ITM

11,54%

Sweeps

0,00%

MESO Neueste Nachrichten

Weitere Nachrichten

Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and...

19 Dezember 2024
GlobeNewswire Inc.

Mesoblast to be Added to Nasdaq Biotechnology Index

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming...

18 Dezember 2024
GlobeNewswire Inc.

Form F-3 - Registration statement by foreign private issuers

13 Dezember 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

09 Dezember 2024
Edgar (US Regulatory)

FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the United States...

05 Dezember 2024
GlobeNewswire Inc.

Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced a key publication...

03 Dezember 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

18 November 2024
Edgar (US Regulatory)

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its...

31 Oktober 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

09 Oktober 2024
Edgar (US Regulatory)

Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered...

30 September 2024
GlobeNewswire Inc.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

MESO - Frequently Asked Questions (FAQ)

What is the current Mesoblast share price?
The current share price of Mesoblast is US$ 15,85
How many Mesoblast shares are in issue?
Mesoblast has 114.178.411 shares in issue
What is the market cap of Mesoblast?
The market capitalisation of Mesoblast is USD 1,4B
What is the 1 year trading range for Mesoblast share price?
Mesoblast has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of Mesoblast?
The price to earnings ratio of Mesoblast is -3,25
What is the cash to sales ratio of Mesoblast?
The cash to sales ratio of Mesoblast is 30,86
What is the reporting currency for Mesoblast?
Mesoblast reports financial results in USD
What is the latest annual turnover for Mesoblast?
The latest annual turnover of Mesoblast is USD 9,25M
What is the latest annual profit for Mesoblast?
The latest annual profit of Mesoblast is USD -87,96M
What is the registered address of Mesoblast?
The registered address for Mesoblast is LEVEL 38, 55 COLLINS STREET, MELBOURNE, VICTORIA, 3000
What is the Mesoblast website address?
The website address for Mesoblast is www.mesoblast.com
Which industry sector does Mesoblast operate in?
Mesoblast operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
APTOAptose Biosciences Inc
US$ 0,373
(119,15%)
47,85M
NVNINVNI Group Ltd
US$ 5,68
(112,73%)
11M
AADIAadi Bioscience Inc
US$ 3,84
(65,52%)
1,15M
XLOXilio Therapeutics Inc
US$ 1,33
(41,79%)
4,46M
AMODAlpha Modus Holdings Inc
US$ 4,49
(28,65%)
9,15k
MTEMMolecular Templates Inc
US$ 0,1903
(-45,63%)
3M
XHGXChange TED Inc
US$ 0,96
(-26,15%)
223,32k
PRFXPainReform Ltd
US$ 8,28
(-25,81%)
1,21M
MOBXMobix Labs Inc
US$ 1,56
(-25,18%)
257,65k
AVGRAvinger Inc
US$ 0,5799
(-19,02%)
909,02k
APTOAptose Biosciences Inc
US$ 0,373
(119,15%)
47,85M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,5899
(3,49%)
24,04M
NVNINVNI Group Ltd
US$ 5,68
(112,73%)
11M
RGTIRigetti Computing Inc
US$ 6,80
(-8,97%)
5,3M
NVDANVIDIA Corporation
US$ 130,7099
(0,02%)
4,76M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
MESO
Mesoblast
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten